Guidelines for the Management of Sexually Transmitted Infections. February 2004
(2004; 88 pages)
Table of Contents
View the documentPREFACE
Open this folder and view contents1. INTRODUCTION
Open this folder and view contents2. TREATMENT OF STI-ASSOCIATED SYNDROMES
Close this folder3. TREATMENT OF SPECIFIC INFECTIONS
Open this folder and view contents3.1. Gonococcal infections
Open this folder and view contents3.2. Chlamydia trachomatis infections (other than lymphogranuloma venereum)
View the document3.3. Lymphogranuloma venereum
Open this folder and view contents3.4. Syphilis
View the document3.5. Chancroid
View the document3.6. Granuloma inguinale (Donovanosis)
Open this folder and view contents3.7. Genital herpes infections
Open this folder and view contents3.8. Venereal warts
View the document3.9. Trichomonas vaginalis infections
Open this folder and view contents3.10. Bacterial vaginosis
Open this folder and view contents3.11. Candidiasis
View the document3.12. Scabies
View the document3.13. Phthiriasis (pediculosis pubis)
Open this folder and view contents4. KEY CONSIDERATIONS UNDERLYING TREATMENTS
Open this folder and view contents5. PRACTICAL CONSIDERATIONS IN STI CASE MANAGEMENT
Open this folder and view contents6. CHILDREN6, ADOLESCENTS AND SEXUALLY TRANSMITTED INFECTIONS
View the documentANNEX. LIST OF PARTICIPANTS
 

3.6. Granuloma inguinale (Donovanosis)

Donovanosis is caused by the intracellular Gram-negative bacterium Calymmatobacterium granulomatis. The disease presents clinically as painless, progressive, ulcerative lesions without regional lymphadenopathy. The lesions are highly vascular and can easily bleed on contact. Treatment should be continued until all lesions have completely epithelialized.

Recommended regimen

• azithromycin, 1g orally on first day, then 500mg orally once a day

OR

• doxycycline, 100mg orally, twice daily

Alternative regimen

• erythromycin, 500mg orally, 4 times daily

OR

• tetracycline, 500mg orally, 4 times daily

OR

• trimethoprim (80mg)/sulfamethoxazole (400mg), 2 tablets orally, twice daily for a minimum of 14 days,

Note

The addition of a parenteral aminoglycoside such as gentamicin should be strongly considered for HIV-infected patients.

Follow-up

Patients should be followed clinically until signs and symptoms have resolved.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019